Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance.
Sadiq
S Tariq
ST
Fredericks
Salim
S
Khoo
Saye H
SH
Rice
Phillip
P
Holt
David W
DW
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood*; D048588:Benzoxazines; D003521:Cyclopropanes; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000097:blood*; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D010078:Oxazines / Q000097:blood*; D018894:Reverse Transcriptase Inhibitors / Q000097:blood
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz